Condition: Crohn Disease · Sponsor: Xian-Janssen Pharmaceutical Ltd.
The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital Sun Yat sen University | Guangzhou, China | Recruiting |
| The Sixth Affiliated Hospital Sun Yat sen University | Guangzhou, China | Recruiting |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| The First Affiliated Hospital of Anhui Medical University | Hefei, China | Recruiting |
| Ruijin Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07310095